CZ303203B6 - Azapolycyklická sloucenina s anelovanou arylskupinou a lécivo s jejím obsahem - Google Patents

Azapolycyklická sloucenina s anelovanou arylskupinou a lécivo s jejím obsahem Download PDF

Info

Publication number
CZ303203B6
CZ303203B6 CZ20022778A CZ20022778A CZ303203B6 CZ 303203 B6 CZ303203 B6 CZ 303203B6 CZ 20022778 A CZ20022778 A CZ 20022778A CZ 20022778 A CZ20022778 A CZ 20022778A CZ 303203 B6 CZ303203 B6 CZ 303203B6
Authority
CZ
Czechia
Prior art keywords
dodeca
azatricyclo
triene
mmol
diazatetracyclo
Prior art date
Application number
CZ20022778A
Other languages
Czech (cs)
English (en)
Other versions
CZ20022778A3 (cs
Inventor
Roanne Palmer Brooks@Paige
Wadsworth Coe@Jotham
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of CZ20022778A3 publication Critical patent/CZ20022778A3/cs
Publication of CZ303203B6 publication Critical patent/CZ303203B6/cs

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/24—Camphidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CZ20022778A 2000-02-25 2001-02-08 Azapolycyklická sloucenina s anelovanou arylskupinou a lécivo s jejím obsahem CZ303203B6 (cs)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/514,002 US6605610B1 (en) 1997-12-31 2000-02-25 Aryl fused azapolycyclic compounds

Publications (2)

Publication Number Publication Date
CZ20022778A3 CZ20022778A3 (cs) 2003-09-17
CZ303203B6 true CZ303203B6 (cs) 2012-05-23

Family

ID=24045406

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20022778A CZ303203B6 (cs) 2000-02-25 2001-02-08 Azapolycyklická sloucenina s anelovanou arylskupinou a lécivo s jejím obsahem

Country Status (39)

Country Link
US (3) US6605610B1 (OSRAM)
EP (2) EP1619192B1 (OSRAM)
JP (1) JP2003524002A (OSRAM)
KR (1) KR100537976B1 (OSRAM)
CN (1) CN1263745C (OSRAM)
AP (1) AP1860A (OSRAM)
AT (2) ATE453643T1 (OSRAM)
AU (2) AU784081B2 (OSRAM)
BG (1) BG65891B1 (OSRAM)
BR (1) BR0108610A (OSRAM)
CA (1) CA2401229C (OSRAM)
CR (1) CR6726A (OSRAM)
CU (1) CU23148A3 (OSRAM)
CY (1) CY1105301T1 (OSRAM)
CZ (1) CZ303203B6 (OSRAM)
DE (2) DE60120366T2 (OSRAM)
DK (2) DK1259489T3 (OSRAM)
DZ (1) DZ3328A1 (OSRAM)
EA (1) EA005316B1 (OSRAM)
EE (1) EE200200475A (OSRAM)
ES (2) ES2263640T3 (OSRAM)
GE (1) GEP20053454B (OSRAM)
HR (1) HRP20020700A2 (OSRAM)
HU (1) HU229482B1 (OSRAM)
IL (2) IL150639A0 (OSRAM)
IS (1) IS2293B (OSRAM)
MA (1) MA26875A1 (OSRAM)
MX (1) MXPA02008311A (OSRAM)
NO (1) NO323608B1 (OSRAM)
NZ (1) NZ519973A (OSRAM)
OA (1) OA12181A (OSRAM)
PL (1) PL365163A1 (OSRAM)
PT (1) PT1259489E (OSRAM)
RS (1) RS51123B (OSRAM)
SI (1) SI1259489T1 (OSRAM)
SK (1) SK12042002A3 (OSRAM)
UA (1) UA74813C2 (OSRAM)
WO (1) WO2001062736A1 (OSRAM)
ZA (1) ZA200206768B (OSRAM)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG102686A1 (en) * 1997-12-31 2004-03-26 Pfizer Prod Inc Aryl fused azapolycyclic compounds
AU2002234836B2 (en) * 2001-04-20 2007-08-23 Pfizer Products Inc. Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
SK1912004A3 (en) * 2001-10-31 2004-09-08 Pfizer Prod Inc Nicotinic acetylcholine receptor agonists in the treatment of restless legs syndrome
CA2468717A1 (en) * 2001-11-30 2003-06-05 Pfizer Products Inc. Aryl fused azapolycyclic compounds
CN1596128A (zh) * 2001-11-30 2005-03-16 辉瑞产品公司 5,7,14－三氮杂四环[10.3.1.0(2,11).0(4,9)]－十六碳－2(11)3,5,7,9－五烯的药物组合物
IN2008CN05409A (OSRAM) 2002-07-18 2015-10-02 Cytos Biotechnology Ag
EP1554041B1 (en) * 2002-10-22 2012-05-23 EMD Millipore Corporation Multi-sided immersion formation of composite structures and method
CN1714075A (zh) * 2002-11-25 2005-12-28 辉瑞产品公司 1,3－取代的茚类的改进制备方法
MXPA05007565A (es) * 2003-01-15 2005-09-21 Pfizer Prod Inc Procedimiento mejorado de preparacion de lactamas policiclicas fusionadas con arilos.
CA2525874C (en) * 2003-05-20 2007-11-27 Pfizer Products Inc. Pharmaceutical compositions of varenicline
MXPA05013084A (es) * 2003-06-04 2006-03-02 Pfizer Prod Inc Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano.
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8580842B2 (en) * 2003-09-30 2013-11-12 Abbott Gmbh & Co. Kg Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
ATE516801T1 (de) * 2003-10-14 2011-08-15 Xenoport Inc Kristalline form eines gamma-aminobuttersäure- analogons
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
WO2006006071A1 (en) * 2004-07-07 2006-01-19 Pfizer Products Inc. Resolution of an aryl-fused azapolycyclic compound
DE602006003320D1 (de) * 2005-02-24 2008-12-04 Pfizer Prod Inc Herstellung eines substituierten chinoxalins von hoher reinheit
AU2007242526A1 (en) * 2006-04-24 2007-11-01 Pfizer Products Inc. Asymmetric membranes for drug delivery devices
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US8486979B2 (en) * 2006-12-12 2013-07-16 Abbvie Inc. 1,2,4 oxadiazole compounds and methods of use thereof
US20080167286A1 (en) 2006-12-12 2008-07-10 Abbott Laboratories Pharmaceutical compositions and their methods of use
UY30846A1 (es) * 2006-12-30 2008-07-31 Abbott Gmbh & Amp Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
WO2009065872A2 (en) * 2007-11-20 2009-05-28 Medichem, S.A. Improved processes for the synthesis of varenicline l-tartrate
JP5595926B2 (ja) * 2007-12-07 2014-09-24 アボット ゲーエムベーハー ウント カンパニー カーゲー ５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
CA2707671C (en) * 2007-12-07 2016-02-02 Abbott Gmbh & Co. Kg 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2010009775A1 (de) * 2007-12-07 2010-01-28 Abbott Gmbh & Co. Kg Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
JP5701607B2 (ja) * 2007-12-07 2015-04-15 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
JP2011516489A (ja) * 2008-03-31 2011-05-26 ユニバーシティ・オブ・サウス・フロリダ 疾患誘発性運動失調症および非運動失調性平衡異常の治療法
WO2009143347A2 (en) * 2008-05-22 2009-11-26 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318695A1 (en) * 2008-06-19 2009-12-24 Vinod Kumar Kansal Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
WO2010023561A1 (en) * 2008-09-01 2010-03-04 Actavis Group Ptc Ehf Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
AU2010214101A1 (en) * 2009-02-11 2011-09-01 Sunovion Pharmaceuticals Inc. Histamine H3 inverse agonists and antagonists and methods of use thereof
EP2435080A2 (en) 2009-05-29 2012-04-04 Abbott Laboratories Pharmaceutical compositions for the treatment of pain
WO2010151524A1 (en) * 2009-06-22 2010-12-29 Teva Pharmaceutical Industries Ltd Solid states forms of varenicline salts and processes for preparation thereof
CN110381919A (zh) 2017-03-03 2019-10-25 西梯茜生命工学股份有限公司 含有伐尼克兰或其药学上可接受的盐的包合复合物的口服施用制剂
AU2020416203A1 (en) * 2020-01-03 2022-06-16 Blue Oak Pharmaceuticals, Inc. Compounds and compositions for treating CNS disorders
CN115322105A (zh) * 2021-05-11 2022-11-11 江苏润安制药有限公司 一种合成艾拉莫德关键中间体的方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
WO2000044755A1 (en) * 1999-01-29 2000-08-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
WO2000045846A1 (fr) * 1999-02-02 2000-08-10 Sanofi-Synthelabo Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
EP1078637A2 (en) * 1999-08-27 2001-02-28 Pfizer Products Inc. Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
WO2002074050A2 (en) * 2001-03-19 2002-09-26 Sloan Kettering Institute For Cancer Research Asymmetric synthesis of (s, s, r)-(-)-actinonin and its analogs and uses therefor
MXPA06000892A (es) * 2003-07-21 2006-03-30 Pfizer Prod Inc Compuestos azapoliciclicos arilo fusionados.
US8123947B2 (en) 2007-10-22 2012-02-28 Baxter International Inc. Priming and air removal systems and methods for dialysis

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999035131A1 (en) * 1997-12-31 1999-07-15 Pfizer Products Inc. Aryl fused azapolycyclic compounds
EP0955301A2 (en) * 1998-04-27 1999-11-10 Pfizer Products Inc. 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylchloline receptors
WO1999055680A1 (en) * 1998-04-29 1999-11-04 Pfizer Products Inc. Aryl fused azapolycyclic compounds
WO2000044755A1 (en) * 1999-01-29 2000-08-03 Abbott Laboratories Diazabicyclic derivatives as nicotinic acetylcholine receptor ligands
WO2000045846A1 (fr) * 1999-02-02 2000-08-10 Sanofi-Synthelabo Compositions pharmaceutiques contenant de la nicotine ou un ligand des recepteurs nicotiniques et un inhibiteur de la monamine oxydase et leur application dans le sevrage tabagique
EP1078637A2 (en) * 1999-08-27 2001-02-28 Pfizer Products Inc. Composition for the treatment and prevention of nicotine addiction containing a nicotine receptor agonist and an anti-depressant or anti-anxiety drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Mazzocchi P. H. et al.:"Synthesis and pharmacological activity of 2,3,4,5-tetrahydro-1,5-methano-1H-3-benzazepines" J. Med. Chem., 1979, vol. 22, no. 4, str. 455-457 (cely dokument) *

Also Published As

Publication number Publication date
US20030130261A1 (en) 2003-07-10
SI1259489T1 (sl) 2006-10-31
AU784081B2 (en) 2006-02-02
HK1050894A1 (en) 2003-07-11
CN1406227A (zh) 2003-03-26
CA2401229A1 (en) 2001-08-30
PT1259489E (pt) 2006-08-31
DK1259489T3 (da) 2006-10-09
US7144882B2 (en) 2006-12-05
BR0108610A (pt) 2002-11-19
HUP0204580A2 (hu) 2003-04-28
RS51123B (sr) 2010-10-31
CN1263745C (zh) 2006-07-12
EP1259489B1 (en) 2006-06-07
MXPA02008311A (es) 2002-12-09
CZ20022778A3 (cs) 2003-09-17
EP1619192B1 (en) 2009-12-30
JP2003524002A (ja) 2003-08-12
ES2263640T3 (es) 2006-12-16
CU23148A3 (es) 2006-06-29
UA74813C2 (en) 2006-02-15
US6605610B1 (en) 2003-08-12
AU2005234671B2 (en) 2008-04-17
EE200200475A (et) 2003-12-15
KR100537976B1 (ko) 2005-12-21
IS2293B (is) 2007-10-15
ZA200206768B (en) 2003-09-23
CY1105301T1 (el) 2010-03-03
AU2874801A (en) 2001-09-03
AP2002002604A0 (en) 2002-09-30
GEP20053454B (en) 2005-02-25
US20030130260A1 (en) 2003-07-10
AP1860A (en) 2008-07-02
ATE328872T1 (de) 2006-06-15
IS6459A (is) 2002-07-05
BG65891B1 (bg) 2010-04-30
DE60140965D1 (de) 2010-02-11
EA200200716A1 (ru) 2003-02-27
BG106908A (bg) 2003-04-30
EP1619192A3 (en) 2006-03-22
NO323608B1 (no) 2007-06-18
ATE453643T1 (de) 2010-01-15
MA26875A1 (fr) 2004-12-20
DK1619192T3 (da) 2010-03-29
DE60120366D1 (de) 2006-07-20
EA005316B1 (ru) 2004-12-30
SK12042002A3 (sk) 2004-02-03
CA2401229C (en) 2007-10-02
HRP20020700A2 (en) 2004-12-31
DE60120366T2 (de) 2007-07-05
IL150639A0 (en) 2003-02-12
HUP0204580A3 (en) 2005-04-28
HU229482B1 (en) 2014-01-28
AU2005234671A1 (en) 2005-12-15
PL365163A1 (en) 2004-12-27
YU59602A (sh) 2005-06-10
IL150639A (en) 2011-10-31
EP1619192A2 (en) 2006-01-25
WO2001062736A1 (en) 2001-08-30
DZ3328A1 (OSRAM) 2001-08-30
KR20030005209A (ko) 2003-01-17
EP1259489A1 (en) 2002-11-27
CR6726A (es) 2003-10-28
US7205300B2 (en) 2007-04-17
NO20024042L (no) 2002-10-17
NZ519973A (en) 2004-04-30
OA12181A (en) 2006-05-09
NO20024042D0 (no) 2002-08-23
ES2336800T3 (es) 2010-04-16

Similar Documents

Publication Publication Date Title
CZ303203B6 (cs) Azapolycyklická sloucenina s anelovanou arylskupinou a lécivo s jejím obsahem
AP1170A (en) Aryl fused azapolycyclic compounds.
EP1383733A2 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds
AU2002234836A1 (en) Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of fee

Effective date: 20150208